Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | Human Immunodeficiency Virus | Research article

Serological diagnosis and prevalence of HIV-1 infection in Russian metropolitan areas

Authors: D. E. Kireev, V. P. Chulanov, G. A. Shipulin, A. V. Semenov, E. V. Tivanova, N. M. Kolyasnikova, E. B. Zueva, V. V. Pokrovskiy, C. Galli

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

HIV infection is a major health problem in Russia. We aimed to assess HIV prevalence in different population groups and to compare the characteristics of 4th generation immunoassays from Abbott, Bio-Rad, Vector-Best, Diagnostic Systems, and Medical Biological Unit.

Methods

The study included 4452 individuals from the general population (GP), 391 subjects at high risk of HIV infection (HR) and 699 with potentially interfering conditions. HIV positivity was confirmed by immunoblot and by HIV RNA, seroconversion and virus diversity panels were also used. HIV avidity was employed to assess recent infections.

Results

The prevalence in GP was 0.40%, higher in males (0.62%) and in people aged < 40 years (0.58%). Patients attending dermo-venereal centers and drug users had a high prevalence (34.1 and 58.8%). Recent infections were diagnosed in 20% of GP and in 4.2% of HR. Assay sensitivity was 100% except for one false negative (99,54%, MBU). Specificity was 99.58–99.89% overall, but as low as 93.26% on HR (Vector-Best). Small differences on early seroconversion were recorded. Only the Abbott assay detected all samples on the viral diversity panel.

Conclusion

HIV infection rate in the high-risk groups suggests that awareness and screening campaigns should be enhanced. Fourth generation assays are adequate but performance differences must be considered.
Appendix
Available only for authorised users
Literature
3.
go back to reference Anon. SanPiN 3.1.5.2826–10 Prevention of HIV infection (version dated 21.07.2016). Anon. SanPiN 3.1.5.2826–10 Prevention of HIV infection (version dated 21.07.2016).
4.
go back to reference Anon. HIV infection, Information Bulletin No. 43, Federal Scientific and Methodological Center for Prevention and Control of AIDS, Federal Budgetary Scientific Institution, Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), 2018. Anon. HIV infection, Information Bulletin No. 43, Federal Scientific and Methodological Center for Prevention and Control of AIDS, Federal Budgetary Scientific Institution, Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), 2018.
5.
go back to reference Simon V, Ho DD, Quarraisha AK. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet. 2006;368:489–504.CrossRef Simon V, Ho DD, Quarraisha AK. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet. 2006;368:489–504.CrossRef
6.
go back to reference Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Available at http://stacks.cdc.gov/view/cdc/23447. Published June 27, 2014. Accessed 24 June 2019. Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Available at http://​stacks.​cdc.​gov/​view/​cdc/​23447. Published June 27, 2014. Accessed 24 June 2019.
7.
go back to reference Hemelaar J. Implications of HIV diversity for the HIV-1 pandemic. J Inf Secur. 2013;66:391–400. Hemelaar J. Implications of HIV diversity for the HIV-1 pandemic. J Inf Secur. 2013;66:391–400.
8.
go back to reference Baranova EN, et al. The ability of modern test systems to confirm early HIV infection. Issues Virol. 2009;54:37–40. Baranova EN, et al. The ability of modern test systems to confirm early HIV infection. Issues Virol. 2009;54:37–40.
9.
go back to reference Ivanova NI, Peksheva OY. The experience of HIV marker detection using a new ELISA diagnostic test system DS-EIA-HIV-AB/AG-SPECTRUM in the laboratories of the centers of AIDS prevention and control of the Privolzhsky Federal District. Clin Lab Diagn. 2009;3:46–8. Ivanova NI, Peksheva OY. The experience of HIV marker detection using a new ELISA diagnostic test system DS-EIA-HIV-AB/AG-SPECTRUM in the laboratories of the centers of AIDS prevention and control of the Privolzhsky Federal District. Clin Lab Diagn. 2009;3:46–8.
10.
go back to reference Raspopina IV, Pankova LV, Kozhevnikova IV. The experience of HIV marker detection using a new ELISA diagnostic test Invitrologic HIV 1,2-AG/AB. Bull Chelyabinsk Reg Clin Hosp. 2013;1:84. Raspopina IV, Pankova LV, Kozhevnikova IV. The experience of HIV marker detection using a new ELISA diagnostic test Invitrologic HIV 1,2-AG/AB. Bull Chelyabinsk Reg Clin Hosp. 2013;1:84.
11.
go back to reference Sharipova IN, et al. Comparative study of the specificity of the test systems for the diagnosis of HIV infection in the serum specimens from pregnant women. Clin Lab Diagn. 2015;60:38–41. Sharipova IN, et al. Comparative study of the specificity of the test systems for the diagnosis of HIV infection in the serum specimens from pregnant women. Clin Lab Diagn. 2015;60:38–41.
12.
go back to reference Lisitsyna ZN, et al. Immune tests and diagnosis of acute HIV infection. HIV Infect Immune Suppression. 2017;9:36–41. Lisitsyna ZN, et al. Immune tests and diagnosis of acute HIV infection. HIV Infect Immune Suppression. 2017;9:36–41.
13.
go back to reference Suligoi B, et al. Avidity index for anti-HIV antibodies: comparison between third- and fourth-generation automated immunoassays. J Clin Microbiol. 2011;49:2610–3.CrossRef Suligoi B, et al. Avidity index for anti-HIV antibodies: comparison between third- and fourth-generation automated immunoassays. J Clin Microbiol. 2011;49:2610–3.CrossRef
14.
go back to reference Suligoi B, et al. HIV avidity index performance using a modified fourth-generation immunoassay to detect recent HIV infections. Clin Chem Lab Med. 2017;55:2010–9.CrossRef Suligoi B, et al. HIV avidity index performance using a modified fourth-generation immunoassay to detect recent HIV infections. Clin Chem Lab Med. 2017;55:2010–9.CrossRef
15.
go back to reference Fiebig EW, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871–9.CrossRef Fiebig EW, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871–9.CrossRef
17.
go back to reference Anon. HIV assays: laboratory performance and other operational characteristics: rapid diagnostic tests (combined detection of HIV-1/2 antibodies and discriminatory detection of HIV-1 and HIV-2 antibodies): report 18. World Health Organization; 2015. ISBN 978 92 4 150811 7. Anon. HIV assays: laboratory performance and other operational characteristics: rapid diagnostic tests (combined detection of HIV-1/2 antibodies and discriminatory detection of HIV-1 and HIV-2 antibodies): report 18. World Health Organization; 2015. ISBN 978 92 4 150811 7.
18.
go back to reference Chaves P, et al. Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab combo assay. J Clin Virol. 2011;52(Suppl 1):S51–5.CrossRef Chaves P, et al. Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab combo assay. J Clin Virol. 2011;52(Suppl 1):S51–5.CrossRef
19.
go back to reference Mitchell EO, et al. Performance comparison of the 4th generation bio-rad laboratories GS HIV combo Ag/Ab EIA on the EVOLIS™ automated system versus Abbott ARCHITECT HIV Ag/Ab combo, Ortho anti-HIV 1+2 EIA on Vitros ECi and Siemens HIV-1/O/2 enhanced on Advia centaur. J Clin Virol. 2013;58(Suppl 1):e79–84.CrossRef Mitchell EO, et al. Performance comparison of the 4th generation bio-rad laboratories GS HIV combo Ag/Ab EIA on the EVOLIS™ automated system versus Abbott ARCHITECT HIV Ag/Ab combo, Ortho anti-HIV 1+2 EIA on Vitros ECi and Siemens HIV-1/O/2 enhanced on Advia centaur. J Clin Virol. 2013;58(Suppl 1):e79–84.CrossRef
20.
go back to reference Lapovok IA, et al. Molecular epidemiological analysis of HIV-1 variants circulating in Russia in 1987—2015. Ther Arch. 2017;89:44–9.CrossRef Lapovok IA, et al. Molecular epidemiological analysis of HIV-1 variants circulating in Russia in 1987—2015. Ther Arch. 2017;89:44–9.CrossRef
22.
go back to reference Gaudy C, et al. Subtype B human immunodeficiency virus (HIV) type 1 mutant that escapes detection in a fourth generation immunoassay for HIV infection. J Clin Microbiol. 2004;42:2847–9.CrossRef Gaudy C, et al. Subtype B human immunodeficiency virus (HIV) type 1 mutant that escapes detection in a fourth generation immunoassay for HIV infection. J Clin Microbiol. 2004;42:2847–9.CrossRef
23.
go back to reference Ly TD, et al. The variable sensitivity of HIV Ag/Ab combination assays in the detection of p24 Ag according to genotype could compromise the diagnosis of early HIV infection. J Clin Virol. 2012;55:121–7.CrossRef Ly TD, et al. The variable sensitivity of HIV Ag/Ab combination assays in the detection of p24 Ag according to genotype could compromise the diagnosis of early HIV infection. J Clin Virol. 2012;55:121–7.CrossRef
24.
go back to reference Qiu X, et al. Comparative evaluation of three FDA-approved HIV Ag/Ab combination tests using a genetically diverse HIV panel and diagnostic specimens. J Clin Virol. 2017;92:62–8.CrossRef Qiu X, et al. Comparative evaluation of three FDA-approved HIV Ag/Ab combination tests using a genetically diverse HIV panel and diagnostic specimens. J Clin Virol. 2017;92:62–8.CrossRef
25.
go back to reference Leeflang MMG, Allerberger F. Sample size calculations for diagnostic studies. Clin Microbiol Infect. 2019;25:777–8.CrossRef Leeflang MMG, Allerberger F. Sample size calculations for diagnostic studies. Clin Microbiol Infect. 2019;25:777–8.CrossRef
26.
go back to reference European Centre for Disease Prevention and Control, WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2018–2017 data. Copenhagen: WHO Regional Office for Europe; 2018. European Centre for Disease Prevention and Control, WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2018–2017 data. Copenhagen: WHO Regional Office for Europe; 2018.
28.
go back to reference Sweeting MJ, et al. Estimating the distribution of the window period for recent HIV infections: a comparison of statistical methods. Stat Med. 2010;29:3194–202.CrossRef Sweeting MJ, et al. Estimating the distribution of the window period for recent HIV infections: a comparison of statistical methods. Stat Med. 2010;29:3194–202.CrossRef
30.
go back to reference Kassanjee R, et al. Viral load criteria and threshold optimization to improve HIV incidence assay characteristics. AIDS. 2016;30:2361–71.CrossRef Kassanjee R, et al. Viral load criteria and threshold optimization to improve HIV incidence assay characteristics. AIDS. 2016;30:2361–71.CrossRef
31.
go back to reference Nicolàs D, et al. Epidemiological changes of acute/recent human immunodeficiency virus type 1 infection in Barcelona, Spain (1997/2015): a prospective cohort study. Clin Microbiol Infect. 2019;25:878–84.CrossRef Nicolàs D, et al. Epidemiological changes of acute/recent human immunodeficiency virus type 1 infection in Barcelona, Spain (1997/2015): a prospective cohort study. Clin Microbiol Infect. 2019;25:878–84.CrossRef
Metadata
Title
Serological diagnosis and prevalence of HIV-1 infection in Russian metropolitan areas
Authors
D. E. Kireev
V. P. Chulanov
G. A. Shipulin
A. V. Semenov
E. V. Tivanova
N. M. Kolyasnikova
E. B. Zueva
V. V. Pokrovskiy
C. Galli
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-05695-z

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue